The value of GATC Health’s AI-powered approach to genomics continues to gain attention as a solution for rapid drug discovery and highly accurate diagnostic tools. The latest article in Healthcare Business Today cites the company’s Multiomics Advanced Technology™ (MAT) as the driver for more accurate predictions about disease states and individual responses to diseases and treatments that will make medicine truly personalized.
The company focuses on Predictive Multiomics™, which analyzes the various biological components of an individual to predictively model what may happen when a disease or treatment is involved. GATC’s MAT differs from other systems that use mathematical, algorithm-based models in that it thinks like human biology, mimicking the interdependence of biological systems to deliver more accurate predictions. Because the platform thinks biologically, its use leads to faster and more accurate detection and the identification of more treatment and intervention options.
GATC Health and its partners are currently investigating the causes and treatments for addiction, identifying in just three weeks three new molecules that could form the basis for a new type of addiction treatment. The company believes that in this case, it has accelerated the drug discovery process by approximately 20 percent.
In addition to its work as a valued partner to pharmaceutical companies, GATC Health has created consumer-based platforms to address a number of pressing health problems. So far, GATC has launched platforms for viral immunity, health and wellness, depression and anxiety, and recently announced its new diabetes platform. To read more, visit www.GATCHealth.com.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.
